Express Scripts sales grow as Trump weighs upending business model

Published



Express Scripts revenue surged in the three months through September, even as speculation mounted that the Trump administration will try to revamp a key piece of its business model.

Sales at the pharmacy benefit manager, which earlier this year won federal approval for its merger with Cigna, grew to $25.6 billion. Profit rose 27 percent to $1.1 billion, or $1.89 a share.

Full midterm coverage.Deeper analysis.

Get unlimited access to Washington Examiner's reporting, expert analysis, and coverage of the midterm elections.

Get Unlimited Access

Cancel anytime.